TET2 and acute myeloid leukemia: To investigate whether TET2 mutation-associated hypermethylation is consistent between AML and CHIP and CCUS, we analyzed data from 90 AML patients with available sequencing and 450k methylation array profiling from The Cancer Genome Atlas (TCGA) LAML cohort, of whom four had a TET2 mutation.